Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial.

Autor:	Paudel R; Dana-Farber Cancer Institute, Boston, MA, USA., Enzinger AC; Dana-Farber Cancer Institute, Boston, MA, USA., Uno H; Dana-Farber Cancer Institute, Boston, MA, USA., Cronin C; Dana-Farber Cancer Institute, Boston, MA, USA., Wong SL; Dartmouth Hitchcock Medical Center, Lebanon, NH, USA., Dizon DS; Lifespan Cancer Institute and Brown University, Providence, RI, USA., Hazard Jenkins H; West Virginia University Cancer Center, Morgantown, WV, USA., Bian J; Maine Medical Center, Portland, ME, USA., Osarogiagbon RU; Baptist Medical Center, Memphis, TN, USA., Jensen RE; National Cancer Institute, Rockville, MD, USA., Mitchell SA; National Cancer Institute, Rockville, MD, USA., Schrag D; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hassett MJ; Dana-Farber Cancer Institute, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Jul 01; Vol. 116 (7), pp. 1137-1144.
DOI:	10.1093/jnci/djae049
Abstrakt:	Background: Optimal methods for deploying electronic patient-reported outcomes to manage symptoms in routine oncologic practice remain uncertain. The electronic symptom management (eSyM) program asks chemotherapy and surgery patients to self-report 12 common symptoms regularly. Feedback from nurses and patients led to changing the recall period from the past 7 days to the past 24 hours. Methods: Using questionnaires submitted during the 16 weeks surrounding the recall period change, we assessed the likelihood of reporting severe or moderate and severe symptoms across 12 common symptoms and separately for the 5 most prevalent symptoms. Interrupted time-series analyses modeled the effects of the change using generalized linear mixed-effects models. Surgery and chemotherapy cohorts were analyzed separately. Study-wide effects were estimated using a meta-analysis method. Results: In total, 1692 patients from 6 institutions submitted 7823 eSyM assessments during the 16 weeks surrounding the recall period change. Shortening the recall period was associated with lower odds of severe symptom reporting in the surgery cohort (odds ratio = 0.65, 95% confidence interval = 0.46 to 0.93; P = .02) and lower odds of moderate and severe symptom reporting in the chemotherapy cohort (odds ratio = 0.83, 95% confidence interval = 0.71 to 0.97; P = .02). Among the most prevalent symptoms, 24-hour recall was associated with a lower rate of reporting postoperative constipation but no differences in reporting rates for other symptoms. Conclusion: A shorter recall period was associated with a reduction in the proportion of patients reporting moderate-severe symptoms. The optimal recall period may vary depending on whether electronic patient-reported outcomes are collected for active symptom management, as a clinical trial endpoint, or another purpose. ClinicalTrials.gov ID NCT03850912. (© The Author(s) 2024. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu